Shares of Repros Therapeutics Inc (NASDAQ:RPRX) ended up by 45.14% during today’s truncated Black Friday trading session, following the Thanksgiving holiday. The surge comes amid news that the company’s treatment for secondary hypogonadism, which results in low testosterone and a reduced sperm count in men, will be reviewed by the FDA on Monday, which suggests that investors are feeling positive about the outcome. The FDA had previously called into question the method used by the company for the analysis of data in its study, which now appears to be resolved. Nonetheless, with its lead candidate, Androxal, approaching potential approval, the investors in our database, some of which are healthcare experts, were not as confident about the stock in the third quarter.
Repros Therapeutics Inc (NASDAQ:RPRX) shareholders have witnessed a decrease in support from the world’s most elite money managers lately. Repros Therapeutics Inc (NASDAQ:RPRX) was in 17 hedge funds’ portfolios at the end of September. There were 19 hedge funds in our database with Repros Therapeutics Inc (NASDAQ:RPRX) holdings at the end of the previous quarter. At the end of this article we will also compare Repros Therapeutics Inc (NASDAQ:RPRX) to other stocks including SeaSpine Holdings Corp (NASDAQ:SPNE), Avinger Inc (NASDAQ:AVGR), and Quinpario Acquisition Corp 2 (NASDAQ:QPACU) to get a better sense of its popularity.
Follow Repros Therapeutics Inc. (NASDAQ:RPRX)
Follow Repros Therapeutics Inc. (NASDAQ:RPRX)
In the 21st century investor’s toolkit there are a multitude of indicators stock traders can use to grade stocks. A pair of the best indicators are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outpace their index-focused peers by a solid amount (see the details here).
Now, let’s take a glance at the new action regarding Repros Therapeutics Inc (NASDAQ:RPRX).
Hedge fund activity in Repros Therapeutics Inc (NASDAQ:RPRX)
At Q3’s end, a total of 17 of the hedge funds tracked by Insider Monkey held long positions in this stock, a dip of 11% from the previous quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few notable hedge fund managers who were boosting their holdings meaningfully (or had already accumulated large positions).
Of the funds tracked by Insider Monkey, Julian Baker and Felix Baker’s Baker Bros. Advisors has the most valuable position in Repros Therapeutics Inc (NASDAQ:RPRX), worth close to $14.5 million, accounting for 0.1% of its total 13F portfolio. Sitting in the two spot is Sarissa Capital Management, managed by Alex Denner, which holds an $8.4 million position; the fund has 2.1% of its 13F portfolio invested in the stock. Some other professional money managers with similar optimism contain Israel Englander’s Millennium Management, Michael Pollack’s Destrier Capital, and Howard Guberman’s Gruss Asset Management.
